This review proposes that the honeymoon phase in type 1 diabetes is driven by adaptive immune tolerance, highlighting a potential therapeutic strategy combining immune tolerance enhancement with metabolic control.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for combined immune tolerance and metabolic interventions in new-onset type 1 diabetes; prospective trials needed before clinical consideration.
Aly et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: